Immutep Ltd
Immutep Limited is an Australia-based late-stage biotechnology company.
The business
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Small Caps Research
No research on Immutep Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise IMM based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial
Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study, which evaluated eftilagimod alfa (efti) in combination with anti-PD-1 therapy Keytruda (pembrolizumab) as first-line therapy for […]
Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials
Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in […]
Immutep reports strong results from efti-KEYTRUDA combination in carcinoma treatment
Clinical-stage biotechnology company Immutep (ASX: IMM) has released top-line results from a Phase IIb trial evaluating eftilagimod alfa (efti) in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a first-line treatment for recurrent and metastatic head and neck squamous cell carcinoma. The results showed that a combination of both drugs can lead to overall response rates […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.